Streetbeat News

ZVSA

ZyVersa Therapeutics, Inc.

https://www.zyversa.com

Industry

Biotechnology

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Open

1.08

Mkt cap

2.5M

Volume

101K

High

1.11

P/E Ratio

N/A

52-wk high

25.00

Low

1.03

Div yield

N/A

52-wk low

0.98

ZyVersa Therapeutics has released its Q3 2024 financial results and provided a business update. Key highlights include the upcoming Phase 2a clinical trial for VAR 200 in diabetic kidney disease patients and the formation of a new Scientific Advisory Board to support the development of IC 100 for obesity-related metabolic complications.

Portfolio Pulse from

November 14, 2024 | 1:30 pm

ZyVersa Therapeutics, iRhythm Technologies, and 3M shares are trading higher due to positive developments. ZyVersa published promising research, iRhythm received FDA clearance, and 3M reported strong earnings and raised guidance.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:09 pm

ZyVersa Therapeutics shares rose after publishing data in Aging Cell, showing obesity's link to neuroinflammation and neurodegenerative diseases.

Portfolio Pulse from Benzinga Newsdesk

October 22, 2024 | 12:02 pm

Zyversa Therapeutics' CEO Stephen Glover has issued a letter to shareholders detailing the company's development plans for its inflammasome ASC inhibitor, IC 100, targeting obesity. The letter outlines anticipated milestones over the next nine months.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:52 am

ZyVersa Therapeutics shares rose following a letter from the CEO to shareholders, detailing obesity development plans for their Inflammasome ASC Inhibitor IC 100.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2024 | 11:51 am

ZyVersa Therapeutics has formed a new Scientific Advisory Board to advance its Inflammasome ASC Inhibitor IC 100, aimed at treating obesity-related metabolic complications. The drug, in combination with incretin therapy, is expected to enhance weight loss and reduce inflammation.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 11:56 am

Intel shares rose 6.9% in pre-market trading due to a strategic collaboration with AWS to advance US-based chip manufacturing. Several other stocks, including Galmed Pharmaceuticals and Smith Micro Software, also saw significant pre-market movements.

Portfolio Pulse from Avi Kapoor

September 17, 2024 | 9:48 am

ZyVersa Therapeutics (NASDAQ:ZVSA) reported a Q2 EPS of $(3.31), beating the analyst consensus estimate of $(3.75) by 11.73%. This represents a significant improvement over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 8:40 pm

ZyVersa Therapeutics has announced the publication of data in a peer-reviewed journal demonstrating that extracellular ASC plays a crucial role in the aggregation and deposition of amyloid A fibrils, which are linked to chronic inflammatory conditions.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 11:56 am

University of Miami researchers have published findings on ZyVersa Therapeutics' ASC Inhibitor, showing its potential as a biomarker for early cognitive decline detection in older adults.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 11:47 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.